From: Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
Adverse event category | Telbivudine (n = 47) | Entecavir (n = 50) | P-value |
---|---|---|---|
Any adverse event | 29 (61.7%) | 29 (58.0%) | 0.71 |
Serious adverse eventsa | 2 (4.3%) | 1 (2.0%) | 0.52 |
Discontinuation due to adverse eventb | 3 (6.4%) | 0 | 0.11 |
Dose reduction due to adverse event | 0 | 0 | - |
Deaths | 0 | 0 | - |
Serum CK >3 x ULN | 3 (6.4%) | 0 | 0.11 |
Myopathy | 1 (2.1%) | 0 | 0.30 |
HCCc, n (%) | 1 (2.1%) | 0 | 0.30 |
Serum creatinine ≥0.5 mg/dL above baseline | 0 | 0 | - |
eGFR <50 mL · min−1 · 1.73 m(2)-1 | 0 | 0 | - |